ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Tempest Therapeutics, Inc. (TPST) stock surged +6.34%, trading at $0.76 on NASDAQ, up from the previous close of $0.71. The stock opened at $0.70, fluctuating between $0.70 and $0.76 in the recent session.
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
Employees | 17 |
Beta | -2.57 |
Sales or Revenue | $0.00 |
5Y Sales Change% | 0% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |